Gleevec

In the US, Gleevec (imatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome, Myelodysplastic Diseases, Myeloproliferative Disorders and Systemic Mastocytosis.

US matches:

• Gleevec

Ingredient matches for Gleevec

Imatinib

Imatinib mesilate (a derivative of Imatinib) is reported as an ingredient of Gleevec in the following countries:

• Canada


• Japan


• Jordan


• South Africa


• Syria


• United States

International Drug Name Search